Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

Source:

Press Release

August 25, 2021
1 min read
Save

FDA grants priority review to tebentafusp for metastatic uveal melanoma

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to tebentafusp for treatment of adults with HLA-A*02:01-positive metastatic uveal melanoma.

Uveal melanoma is an aggressive form of cancer for which treatment options are limited.

Tebentafusp significantly prolonged OS compared with immune checkpoint inhibitors and other standard therapies among previously untreated patients with metastatic uveal melanoma.
Data were derived from Piperno-Neumann S, et al. Abstract CT002. Presented at: American Association for Cancer Research Annual Meeting (virtual meeting); April 10-15, 2021.

Tebentafusp (Immunocore Holdings) is a novel bispecific protein comprised of a soluble T-cell receptor fused to an anti-CD3 immune-effector function.

The agent targets gp100, a lineage antigen expressed in melanocytes and melanoma, according to an Immunocore-issued press release.

The FDA based priority review on findings from the randomized phase 3 IMCgp100-202 trial, which compared tebentafusp with investigator’s choice of therapy — pembrolizumab (Keytruda, Merck; 82%), ipilimumab (Yervoy, Bristol Myers Squibb; 12%) or dacarbazine (6%) — for patients with previously untreated metastatic uveal melanoma.

As Healio previously reported, the trial achieved its primary endpoint of OS.

Results presented at this year’s virtual American Association for Cancer Research Annual Meeting showed tebentafusp monotherapy conferred a statistically significant improvement in OS compared with investigator’s choice of therapy (HR = 0.51; 95% CI, 0.37-0.71).

The FDA is expected to make a decision on approval by Feb. 23.

The agency previously granted breakthrough therapy designation to tebentafusp for treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma.